Symbols / CMPS Stock $10.62 -3.10% COMPASS Pathways plc
CMPS (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-05-14 | main | Morgan Stanley | Overweight → Overweight | $17 |
| 2026-05-14 | main | RBC Capital | Outperform → Outperform | $22 |
| 2026-05-13 | reit | BTIG | Buy → Buy | $14 |
| 2026-05-04 | init | Jefferies | — → Buy | $18 |
| 2026-04-28 | reit | HC Wainwright & Co. | Buy → Buy | $70 |
| 2026-04-24 | init | B. Riley Securities | — → Buy | $17 |
| 2026-04-20 | reit | BTIG | Buy → Buy | $14 |
| 2026-03-26 | main | Canaccord Genuity | Buy → Buy | $18 |
| 2026-03-25 | main | Morgan Stanley | Overweight → Overweight | $16 |
| 2026-03-02 | main | HC Wainwright & Co. | Buy → Buy | $70 |
| 2026-02-18 | main | Canaccord Genuity | Buy → Buy | $20 |
| 2026-02-18 | main | Morgan Stanley | Overweight → Overweight | $18 |
| 2026-02-18 | main | RBC Capital | Outperform → Outperform | $22 |
| 2026-01-23 | main | RBC Capital | Outperform → Outperform | $21 |
| 2025-11-05 | main | Morgan Stanley | Overweight → Overweight | $11 |
| 2025-10-13 | main | BTIG | Buy → Buy | $14 |
| 2025-08-04 | main | HC Wainwright & Co. | Buy → Buy | $40 |
| 2025-08-01 | main | Canaccord Genuity | Buy → Buy | $15 |
| 2025-07-15 | reit | HC Wainwright & Co. | Buy → Buy | $45 |
| 2025-06-23 | down | Evercore ISI Group | Outperform → In-Line | $6 |
- Mental health biotech Compass Pathways joins RBC investor healthcare talks - Stock Titan hu, 14 May 2026 10
- Why COMPASS Pathways (CMPS) Is Up 13.1% After FDA Fast-Track Moves For COMP360 Profit Shift - simplywall.st hu, 14 May 2026 22
- Why This Psychedelics Stock Just Took A Trip To A Fresh High - Investor's Business Daily Wed, 13 May 2026 20
- Compass Pathways jumps after earnings beat and accelerated FDA review progress (CMPS) - Yahoo Finance Wed, 13 May 2026 12
- What makes COMPASS Pathways PLC sponsored ADR (CMPS) a strong momentum stock: Buy now? - MSN Mon, 11 May 2026 17
- CMPS Stock 12‑Month Price Target Raised to $21.37, Implies 128% Upside - TradingView Wed, 13 May 2026 22
- Analysts Offer Insights on Healthcare Companies: DarioHealth (DRIO), NeuroOne Medical Technologies (NMTC) and COMPASS Pathways (CMPS) - The Globe and Mail hu, 14 May 2026 19
- COMPASS PATHWAYS ($CMPS) Releases Q1 2026 Earnings - Quiver Quantitative Wed, 13 May 2026 10
- COMPASS Pathways Plc (CMPS) Stock Analysis: Exploring a Promising 128% Upside Potential - DirectorsTalk Interviews Fri, 08 May 2026 09
- Compass Pathways shares rise on Q1 results, accelerated FDA review - Proactive financial news Wed, 13 May 2026 12
- Psychedelic depression therapy tested in 1,000 people lines up for faster FDA review - Stock Titan Wed, 13 May 2026 10
- Has The Surge In COMPASS Pathways (CMPS) Shares Left The Valuation Looking Stretched? - simplywall.st Fri, 24 Apr 2026 07
- Is COMPASS Pathways (CMPS) Outperforming Other Medical Stocks This Year? - Yahoo Finance Fri, 24 Apr 2026 07
- Compass Pathways (CMPS) builds cash to $466M as COMP360 Phase 3 trials succeed - Stock Titan Wed, 13 May 2026 10
- CMPS on track for best week ever on FDA push for psychedelics - MSN Mon, 27 Apr 2026 02
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
175.29
+11.57%
|
157.11
+26.66%
|
124.04
+29.24%
|
95.98
|
| Research And Development |
|
118.44
-0.51%
|
119.04
+36.02%
|
87.52
+34.53%
|
65.05
|
| Selling General And Administration |
|
60.60
+2.43%
|
59.17
+19.77%
|
49.40
+8.93%
|
45.35
|
| General And Administrative Expense |
|
60.60
+2.43%
|
59.17
+19.77%
|
49.40
+8.93%
|
45.35
|
| Salaries And Wages |
|
28.22
-13.52%
|
32.63
+22.86%
|
26.56
+15.85%
|
22.93
|
| Other Gand A |
|
32.38
+22.03%
|
26.54
+16.17%
|
22.84
+1.86%
|
22.43
|
| Total Expenses |
|
175.29
+11.57%
|
157.11
+26.66%
|
124.04
+29.24%
|
95.98
|
| Operating Income |
|
-175.29
-11.57%
|
-157.11
-26.66%
|
-124.04
-29.24%
|
-95.98
|
| Total Operating Income As Reported |
|
-179.04
-0.47%
|
-178.21
-30.15%
|
-136.92
-24.02%
|
-110.40
|
| EBITDA |
|
-285.60
-91.92%
|
-148.82
-29.14%
|
-115.24
-26.96%
|
-90.77
|
| Normalized EBITDA |
|
-166.51
-12.67%
|
-147.78
-24.27%
|
-118.92
-29.85%
|
-91.59
|
| Reconciled Depreciation |
|
0.22
-7.30%
|
0.23
-3.72%
|
0.24
-26.67%
|
0.33
|
| EBIT |
|
-285.82
-91.76%
|
-149.05
-29.07%
|
-115.48
-26.77%
|
-91.10
|
| Total Unusual Items |
|
-119.09
-11439.73%
|
-1.03
-128.00%
|
3.69
+348.96%
|
0.82
|
| Total Unusual Items Excluding Goodwill |
|
-119.09
-11439.73%
|
-1.03
-128.00%
|
3.69
+348.96%
|
0.82
|
| Net Income |
|
-287.86
-85.57%
|
-155.12
-30.94%
|
-118.46
-29.46%
|
-91.50
|
| Pretax Income |
|
-290.33
-89.11%
|
-153.53
-30.46%
|
-117.68
-29.19%
|
-91.10
|
| Net Non Operating Interest Income Expense |
|
2.67
-29.66%
|
3.79
+56.63%
|
2.42
|
0.00
|
| Interest Expense Non Operating |
|
4.52
+0.85%
|
4.48
+103.22%
|
2.20
|
0.00
|
| Net Interest Income |
|
2.67
-29.66%
|
3.79
+56.63%
|
2.42
|
0.00
|
| Interest Expense |
|
4.52
+0.85%
|
4.48
+103.22%
|
2.20
|
0.00
|
| Interest Income Non Operating |
|
7.18
-13.13%
|
8.27
+78.84%
|
4.62
|
—
|
| Interest Income |
|
7.18
-13.13%
|
8.27
+78.84%
|
4.62
|
—
|
| Other Income Expense |
|
-117.71
-56220.57%
|
-0.21
-105.30%
|
3.94
-19.27%
|
4.88
|
| Other Non Operating Income Expenses |
|
1.38
+67.68%
|
0.82
+222.75%
|
0.26
-93.72%
|
4.06
|
| Gain On Sale Of Security |
|
-119.09
-11439.73%
|
-1.03
-128.00%
|
3.69
+348.96%
|
0.82
|
| Tax Provision |
|
-2.47
-255.14%
|
1.59
+104.36%
|
0.78
+91.18%
|
0.41
|
| Tax Rate For Calcs |
|
0.00
-96.59%
|
0.00
+31.58%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
-1.01
-293.17%
|
-0.26
-136.84%
|
0.70
+348.96%
|
0.16
|
| Net Income Including Noncontrolling Interests |
|
-287.86
-85.57%
|
-155.12
-30.94%
|
-118.46
-29.46%
|
-91.50
|
| Net Income From Continuing Operation Net Minority Interest |
|
-287.86
-85.57%
|
-155.12
-30.94%
|
-118.46
-29.46%
|
-91.50
|
| Net Income From Continuing And Discontinued Operation |
|
-287.86
-85.57%
|
-155.12
-30.94%
|
-118.46
-29.46%
|
-91.50
|
| Net Income Continuous Operations |
|
-287.86
-85.57%
|
-155.12
-30.94%
|
-118.46
-29.46%
|
-91.50
|
| Normalized Income |
|
-169.79
-10.00%
|
-154.35
-27.09%
|
-121.45
-31.77%
|
-92.17
|
| Net Income Common Stockholders |
|
-287.86
-85.57%
|
-155.12
-30.94%
|
-118.46
-29.46%
|
-91.50
|
| Diluted EPS |
|
-3.08
-33.91%
|
-2.30
+0.86%
|
-2.32
-7.41%
|
-2.16
|
| Basic EPS |
|
-3.08
-33.91%
|
-2.30
+0.86%
|
-2.32
-7.41%
|
-2.16
|
| Basic Average Shares |
|
93.50
+38.56%
|
67.48
+0.00%
|
67.48
+59.02%
|
42.44
|
| Diluted Average Shares |
|
93.50
+38.56%
|
67.48
+0.00%
|
67.48
+59.02%
|
42.44
|
| Diluted NI Availto Com Stockholders |
|
-287.86
-85.57%
|
-155.12
-30.94%
|
-118.46
-29.46%
|
-91.50
|
| Other Taxes |
|
-3.75
+82.24%
|
-21.10
-63.86%
|
-12.88
+10.74%
|
-14.42
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
275.99
|
| Current Assets |
|
261.30
|
| Cash Cash Equivalents And Short Term Investments |
|
220.20
|
| Cash And Cash Equivalents |
|
220.20
|
| Receivables |
|
28.93
|
| Taxes Receivable |
|
28.93
|
| Prepaid Assets |
|
9.83
|
| Current Deferred Assets |
|
—
|
| Restricted Cash |
|
0.44
|
| Other Current Assets |
|
1.90
|
| Total Non Current Assets |
|
14.69
|
| Net PPE |
|
4.73
|
| Gross PPE |
|
4.73
|
| Accumulated Depreciation |
|
—
|
| Properties |
|
—
|
| Machinery Furniture Equipment |
|
—
|
| Other Properties |
|
4.73
|
| Leases |
|
—
|
| Investments And Advances |
|
0.47
|
| Other Investments |
|
0.47
|
| Non Current Accounts Receivable |
|
—
|
| Non Current Deferred Assets |
|
3.34
|
| Non Current Deferred Taxes Assets |
|
3.34
|
| Non Current Prepaid Assets |
|
5.96
|
| Other Non Current Assets |
|
0.20
|
| Total Liabilities Net Minority Interest |
|
50.24
|
| Current Liabilities |
|
19.60
|
| Payables And Accrued Expenses |
|
9.09
|
| Payables |
|
5.89
|
| Accounts Payable |
|
5.89
|
| Current Accrued Expenses |
|
3.19
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
7.07
|
| Total Tax Payable |
|
0.00
|
| Income Tax Payable |
|
0.00
|
| Current Debt And Capital Lease Obligation |
|
2.41
|
| Current Debt |
|
—
|
| Other Current Borrowings |
|
—
|
| Current Capital Lease Obligation |
|
2.41
|
| Other Current Liabilities |
|
1.04
|
| Total Non Current Liabilities Net Minority Interest |
|
30.64
|
| Long Term Debt And Capital Lease Obligation |
|
30.64
|
| Long Term Debt |
|
28.76
|
| Long Term Capital Lease Obligation |
|
1.88
|
| Stockholders Equity |
|
225.74
|
| Common Stock Equity |
|
225.74
|
| Capital Stock |
|
0.64
|
| Common Stock |
|
0.64
|
| Share Issued |
|
61.94
|
| Ordinary Shares Number |
|
61.94
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
621.64
|
| Retained Earnings |
|
-379.61
|
| Gains Losses Not Affecting Retained Earnings |
|
-16.93
|
| Other Equity Adjustments |
|
-16.93
|
| Total Equity Gross Minority Interest |
|
225.74
|
| Total Capitalization |
|
254.50
|
| Working Capital |
|
241.69
|
| Invested Capital |
|
254.50
|
| Total Debt |
|
33.05
|
| Capital Lease Obligations |
|
4.29
|
| Net Tangible Assets |
|
225.74
|
| Tangible Book Value |
|
225.74
|
| Other Equity Interest |
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-157.24
-31.93%
|
-119.19
-22.40%
|
-97.38
+7.66%
|
-105.45
|
| Cash Flow From Continuing Operating Activities |
|
-157.24
-31.93%
|
-119.19
-22.40%
|
-97.38
+7.66%
|
-105.45
|
| Net Income From Continuing Operations |
|
-287.86
-85.57%
|
-155.12
-30.94%
|
-118.46
-29.46%
|
-91.50
|
| Depreciation Amortization Depletion |
|
0.22
-7.30%
|
0.23
-3.72%
|
0.24
-26.67%
|
0.33
|
| Depreciation And Amortization |
|
0.22
-7.30%
|
0.23
-3.72%
|
0.24
-26.67%
|
0.33
|
| Other Non Cash Items |
|
9.66
+160.41%
|
3.71
+39.24%
|
2.66
+25.26%
|
2.13
|
| Stock Based Compensation |
|
13.59
-30.37%
|
19.52
+12.97%
|
17.28
+31.65%
|
13.12
|
| Operating Gains Losses |
|
121.41
+15980.66%
|
0.76
+129.30%
|
-2.58
-325.85%
|
1.14
|
| Gain Loss On Investment Securities |
|
122.56
|
—
|
—
|
—
|
| Net Foreign Currency Exchange Gain Loss |
|
-1.15
-252.58%
|
0.76
+128.85%
|
-2.62
-329.36%
|
1.14
|
| Gain Loss On Sale Of PPE |
|
—
|
0.00
-100.00%
|
0.04
|
0.00
|
| Change In Working Capital |
|
-14.25
-221.55%
|
11.72
+236.58%
|
3.48
+111.36%
|
-30.67
|
| Change In Prepaid Assets |
|
-7.95
-336.93%
|
3.35
-27.32%
|
4.62
+115.88%
|
-29.07
|
| Change In Payables And Accrued Expense |
|
-3.87
-138.92%
|
9.95
+299.96%
|
2.49
+13.93%
|
2.18
|
| Change In Accrued Expense |
|
-5.91
-275.90%
|
3.36
+106.84%
|
1.62
+616.88%
|
-0.31
|
| Change In Payable |
|
2.03
-69.14%
|
6.59
+662.73%
|
0.86
-65.40%
|
2.50
|
| Change In Account Payable |
|
2.03
-69.14%
|
6.59
+662.73%
|
0.86
-65.40%
|
2.50
|
| Change In Other Working Capital |
|
0.02
-96.65%
|
0.69
+141.30%
|
-1.66
+2.35%
|
-1.70
|
| Change In Other Current Assets |
|
—
|
—
|
—
|
-0.31
|
| Change In Other Current Liabilities |
|
-2.45
-8.26%
|
-2.27
-15.62%
|
-1.96
+5.86%
|
-2.08
|
| Investing Cash Flow |
|
—
|
0.00
+100.00%
|
-0.06
+89.26%
|
-0.60
|
| Cash Flow From Continuing Investing Activities |
|
—
|
0.00
+100.00%
|
-0.06
+89.26%
|
-0.60
|
| Net PPE Purchase And Sale |
|
—
|
0.00
+100.00%
|
-0.06
+89.26%
|
-0.60
|
| Purchase Of PPE |
|
—
|
0.00
+100.00%
|
-0.07
+88.93%
|
-0.60
|
| Sale Of PPE |
|
—
|
0.00
-100.00%
|
0.00
|
0.00
|
| Capital Expenditure |
|
—
|
—
|
-0.07
+88.93%
|
-0.60
|
| Net Investment Purchase And Sale |
|
—
|
—
|
—
|
0.00
|
| Purchase Of Investment |
|
—
|
—
|
—
|
0.00
|
| Financing Cash Flow |
|
140.71
+120.47%
|
63.82
-63.28%
|
173.83
+16614.42%
|
1.04
|
| Cash Flow From Continuing Financing Activities |
|
140.71
+120.47%
|
63.82
-63.28%
|
173.83
+16614.42%
|
1.04
|
| Net Issuance Payments Of Debt |
|
—
|
0.00
-100.00%
|
29.59
|
0.00
|
| Issuance Of Debt |
|
—
|
0.00
-100.00%
|
29.59
|
0.00
|
| Long Term Debt Issuance |
|
—
|
0.00
-100.00%
|
29.59
|
0.00
|
| Net Long Term Debt Issuance |
|
—
|
0.00
-100.00%
|
29.59
|
0.00
|
| Short Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Net Short Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Net Common Stock Issuance |
|
140.36
+435.33%
|
26.22
-81.91%
|
144.94
+32839.77%
|
0.44
|
| Proceeds From Stock Option Exercised |
|
0.35
-99.06%
|
37.84
+10620.68%
|
0.35
-41.17%
|
0.60
|
| Net Other Financing Charges |
|
0.00
+100.42%
|
-0.24
+77.09%
|
-1.04
|
—
|
| Changes In Cash |
|
-16.53
+70.15%
|
-55.36
-172.47%
|
76.39
+172.75%
|
-105.01
|
| Effect Of Exchange Rate Changes |
|
1.04
+438.66%
|
0.19
-77.62%
|
0.87
+103.47%
|
-24.96
|
| Beginning Cash Position |
|
165.47
-25.00%
|
220.64
+53.88%
|
143.38
-47.55%
|
273.35
|
| End Cash Position |
|
149.99
-9.36%
|
165.47
-25.00%
|
220.64
+53.88%
|
143.38
|
| Free Cash Flow |
|
-157.24
-31.93%
|
-119.19
-22.31%
|
-97.44
+8.11%
|
-106.05
|
| Interest Paid Supplemental Data |
|
3.05
-0.65%
|
3.07
+144.82%
|
1.25
|
—
|
| Income Tax Paid Supplemental Data |
|
0.76
-32.65%
|
1.12
-54.10%
|
2.44
|
—
|
| Common Stock Issuance |
|
140.36
+435.33%
|
26.22
-81.91%
|
144.94
+32839.77%
|
0.44
|
| Issuance Of Capital Stock |
|
140.36
+435.33%
|
26.22
-81.91%
|
144.94
+32839.77%
|
0.44
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-05-13 View
- 10-Q2026-05-13 View
- 42026-03-27 View
- 42026-03-27 View
- 42026-03-27 View
- 10-K2026-03-24 View
- 8-K2026-03-24 View
- 42026-03-13 View
- 42026-03-13 View
- 42026-03-03 View
- 8-K2026-02-19 View
- 8-K2026-02-17 View
- 42026-02-03 View
- 8-K2026-01-07 View
- 10-Q2025-11-04 View
- 8-K2025-11-04 View
- 42025-10-31 View
- 8-K2025-10-29 View
- 42025-08-04 View
- 8-K2025-07-31 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|